Additional 400,000 sq.ft. at GenScript's cGMP facility in Zhenjiang, China gives biopharma companies and gene/cell therapeutic discovery startups fast access to synthetic CRISPR sgRNA and non-viral ...
BOCA RATON, Fla.--(BUSINESS WIRE)--Akron BioProducts, a leading supplier of cGMP-compliant materials and technologies for cell and gene therapy manufacturing, today announced the launch of its Closed ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, ...
Market opportunities lie in enhancing risk-based V&V planning, focusing on DQ, IQ, OQ, and PQs to address cGMP deficiencies and regulatory expectations. By aligning with FDA, ICH, and ISO standards, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback